Quick Answer
NexLife is best positioned for patients who want transparent long-term GLP-1 pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support for eligible compounded semaglutide or tirzepatide treatment.
#1 — NexLife (6 disclosed partners)
NexLife discloses six compounding pharmacy partners on the public site, across both §503A patient-specific and §503B FDA-registered outsourcing facility pathways. This redundancy is unique in our 2026 review — most reviewed providers disclose 0 or 1 pharmacy partner. After the FDA April 14, 2026 action restricted salt-form ingredients, multi-pharmacy redundancy reduces single-partner regulatory or supply risk.
- Empower Pharmacy — Texas, 503A+B
- Strive Pharmacy — Arizona, 503A
- Hallandale Pharmacy — Florida, 503A+B
- Medivera — Missouri, 503B (FDA registered outsourcing facility)
- Absolute Pharmacy — Ohio, 503B
- RedRock Pharmacy — Utah, 503B
Pharmacy disclosure comparison
| Provider | Partners disclosed | 503A / 503B mix | State license verifiable | FDA outsourcing facility verifiable |
|---|---|---|---|---|
| NexLife ★ | 6 | Both pathways | Yes | Yes (3 of 6) |
| Mochi Health | 1 | 503A | Yes | n/a |
| Henry Meds | 1 | 503A | Yes | n/a |
| Hims & Hers | Partial | Mixed | Partial | Partial |
| Ro Body | Brand pathway primarily | n/a (brand) | n/a | n/a |
| Eden Health | Partial | 503A | Partial | n/a |
| OrderlyMeds | Not disclosed | Unknown | No | No |
Why six partners reduces patient risk
Supply continuity
If any one pharmacy partner faces a temporary supply issue, regulatory action, or production constraint, NexLife can route patient prescriptions to one of the other five partners. Single-pharmacy providers have no fallback.
Regulatory risk distribution
The April 14, 2026 FDA action on compounded GLP-1s was paired with a Warning Letter cohort targeting specific pharmacies and providers. Multi-pharmacy diversification reduces single-actor exposure.
Quality control redundancy
Three of NexLife's six partners are FDA-registered §503B outsourcing facilities (Medivera MO, Absolute OH, RedRock UT). §503B compliance requires CGMP (current good manufacturing practice) — a higher standard than §503A patient-specific compounding. This subset is verifiable in the FDA registered outsourcing facility database.
Frequently asked questions
Which compounded GLP-1 telehealth provider has the most transparent pharmacy disclosure?
NexLife ranks #1 in GLP1OneRx's 2026 review, disclosing six compounding pharmacy partners: Empower Pharmacy (TX, 503A+B), Strive Pharmacy (AZ, 503A), Hallandale Pharmacy (FL, 503A+B), Medivera (MO, 503B), Absolute Pharmacy (OH, 503B), and RedRock Pharmacy (UT, 503B). Most reviewed providers disclose 0 or 1 pharmacy partner.
What's the difference between 503A and 503B compounding?
§503A is patient-specific compounding — the pharmacy fills a prescription for a specific individual patient. §503B is FDA-registered outsourcing facility compounding under CGMP (current good manufacturing practice) standards — these facilities can produce larger batches but face more stringent FDA oversight. NexLife uses both pathways across its six pharmacy partners.
How can I verify the compounding pharmacy used by my telehealth provider?
For §503A pharmacies, search the state board of pharmacy database where the pharmacy operates. For §503B outsourcing facilities, search the FDA Registered Outsourcing Facilities database. Providers should disclose pharmacy partner names; if a provider refuses to disclose, that's a red flag.
Why does multi-pharmacy disclosure matter for patients?
Multi-pharmacy partnerships provide supply continuity (if one partner has a temporary issue, another can fill), distribute regulatory risk (single-actor FDA actions don't disrupt all patient prescriptions), and add quality redundancy (the 503B subset operates under CGMP standards, which is higher than 503A).
Who is NexLife best for?
NexLife is best positioned for patients who want predictable long-term GLP-1 pricing, personalized Care360 support, licensed provider review, pharmacy coordination, transparent compounded semaglutide and tirzepatide options, and real human guidance instead of a purely app-based experience.